Zilovertamab vedotin clinical trials
6 indexed studies · 5 currently recruiting
- RecruitingPHASE1, PHASE2
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
This study looks at new treatments for bladder cancer (and related areas) that has spread or is advanced, especially when previous treatments haven't worked well. It tests different medicines to see if they can help patients whose cancer hasn't responded to standard immune-boosting drugs.
For: Urothelial CarcinomaUnited States · Australia · Canada - RecruitingPHASE2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
This study compares two treatments for a fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL), specifically a type called GCB DLBCL. Researchers want to see if a new drug, zilovertamab vedotin, when combined with standard therapy, works better than another combination in shrinking the cancer.
For: Lymphoma, Large B-Cell, DiffuseUnited States · Belgium · Germany - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
For: DLBCL · Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
This study looks at new treatments, zilovertamab vedotin alone or with nemtabrutinib, for certain B-cell lymphomas like Mantle Cell Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia. It checks how safe and effective these treatments are for people whose cancer has returned or didn’t respond to previous therapies.
For: Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma · Follicular LymphomaUnited States · Brazil · Canada - RecruitingPHASE1, PHASE2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
This study is testing a new drug, Zilovertamab Vedotin, for children and young adults aged 6 months to 25 years with certain blood cancers (like some types of leukaemia and lymphoma) and solid tumours (like neuroblastoma and Ewing sarcoma) that have come back or not responded to previous treatments.
For: B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Burkitt LymphomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
This study looks at a new drug, zilovertamab vedotin, combined with standard treatment for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). Researchers want to see if this new combination helps people live longer without their cancer growing or spreading, compared to standard treatment alone.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia